Eden Research (LON:EDEN) Shares Down 13.2% – Should You Sell?

Posted by Gary Stephens on Apr 1st, 2025

Shares of Eden Research plc (LON:EDEN – Get Free Report) fell 13.2% during mid-day trading on Monday . The company traded as low as GBX 2.26 ($0.03) and last traded at GBX 2.37 ($0.03). 1,775,147 shares traded hands during trading, an increase of 133% from the average session volume of 762,776 shares. The stock had previously closed at GBX 2.73 ($0.04).

Eden Research Stock Down 13.2 %

The company has a quick ratio of 2.42, a current ratio of 3.80 and a debt-to-equity ratio of 1.26. The firm has a 50-day moving average price of GBX 3.41 and a two-hundred day moving average price of GBX 3.74. The company has a market capitalization of £12.64 million, a P/E ratio of -8.30 and a beta of 0.92.

Insider Transactions at Eden Research

In related news, insider Lykele van der Broek acquired 256,000 shares of the stock in a transaction dated Thursday, February 6th. The stock was bought at an average price of GBX 4 ($0.05) per share, with a total value of £10,240 ($13,229.97). Also, insider Alexander John Abrey purchased 167,947 shares of Eden Research stock in a transaction on Tuesday, March 4th. The shares were purchased at an average cost of GBX 3 ($0.04) per share, with a total value of £5,038.41 ($6,509.57). In the last ninety days, insiders purchased 964,487 shares of company stock valued at $3,690,001. Corporate insiders own 14.02% of the company’s stock.

Eden Research Company Profile

(Get Free Report)

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

Eden’s products are formulated with terpene active ingredients, based on natural plant defence metabolites.